Whilst we are currently focussed on Remestemcel-L’s ability to relieve the acute impact of COVID-19 particularly on the lungs during ARDS, could Mesoblast also have additional markets to serve in either preventing or treating the long-term impacts of COVID-19 on the heart?
COVID-19 survivors have high prevalence of abnormal heartconditions
Information has recently been released from a study undertaken at Edinburgh University (funded by the British Heart Foundation) which has identified that 55% of 1261 people who had survived COVID-19 have had abnormal changes to the function of their heart with one in seven showing evidence of severe disfunction.
https://www.sciencefocus.com/news/coronavirus-may-have-devastating-impact-on-the-heart/https://www.theguardian.com/science/2020/jul/13/heart-scans-of-covid-19-patients-show-range-of-abnormalities
Inflammation from over-reaction from immune response causing heart failure
An Australian study is presently underway regarding long-term consequences of COVID-19 on the heart. Sean Lal is a cardiologist from RPA hospital who postulated that inflammation arising from the immune response during COVID-19 pneumonia could be causing scarring of the heart. He cited that 1/3 of patients from ICU had elevated troponin which is a specific blood marker of heart damage. He noted surprisingly high prevalence in youngpeople.
Studies are underway to assess what the long-term impacts may be. Sean Lal suggested arrhythmia or heart failure are likely future symptoms of COVID-19 survivors who have suffered this damage.https://iview.abc.net.au/show/drumRefer to the latest episode of the Drum (14 July) from about 23:50
Could Remestemcel-L reduce these impacts?
Mesoblast have described that Remestemcel-L can modulate the immune response during ARDS to help control inflammation. We keenly await the results of Mesoblast’s current trial to assess of benefits to ARDS patients with a particular focus on all-cause mortality after 30 days. I wonder if the efficacy of this treatment might be proven to be even greater after a longer period?
Could Revascor potentially have a significantly larger future market?
Mesoblast have identified that chronic heart failure affects about 2% of US citizens and that its prevalence is expected to grow 46% by 2030, affecting more than 8 million Americans. As we see increasing numbers of cases of COVID-19 throughout the US, could we infer that the future prevalence of CHF could be significantly higher?
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-4478
-
-
- There are more pages in this discussion • 13,850 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | $1.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.46 | 27045 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | 1.450 |
1 | 2574 | 1.440 |
1 | 15000 | 1.435 |
2 | 11400 | 1.430 |
1 | 15000 | 1.425 |
Price($) | Vol. | No. |
---|---|---|
1.455 | 14000 | 1 |
1.460 | 14000 | 1 |
1.465 | 14000 | 1 |
1.480 | 50134 | 1 |
1.485 | 40331 | 2 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |